Kornimate/medical-research-clean huggingface dataset:
efficacy of extracorporeal shock wave therapy, laser therapy and cryotherapy in patients having sacroiliitis

Conditions: Sacroilitis

Summary: this research aimed to determine the effect of extracorporeal shock wave therapy, laser therapy and cryotherapy on ppt, pain and functional disability in patients having sacroiliitis.

the study will be based on a three-arm parallel group randomized control design. sixty participants of sacroiliitis will be recruited from the physiotherapy department, at najran university, k.s.a. study objectives and procedure will be properly explained and written informed consent will be obtained at the beginning of the study. all the participants will be randomly divided into three groups 1, 2 and 3. all the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week. from the 2nd week: group 1 will be administered eswt plus exercise, group 2 will be administered laser plus exercise, and group 3 will be administered cryotherapy and exercise.

Eligibility criteria:
inclusion criteria: * pain in one or both buttocks, hip pain, thigh pain, or even pain more distal. * patients may report that their pain is worse after sitting for prolonged periods or with rotational movements that will be intensified when bending laterally or backward and * positive outcome in a minimum of three out of five pain-provocation tests (i.e., compression test, distraction test, faber sign, gaenslen test, and thigh thrust. * pain close to the posterior superior iliac spine and the patient could point with a single finger to the location of pain (fortin finger test). exclusion criteria: * the participant who had undergone surgery or experienced significant trauma to the spine, pelvis, lower limb, chest, or abdomen within the past 12 months. * the participants with lower extremity musculoskeletal disorders, localized spinal pathology, congenital anomalies of the hip, pelvis, or spine that limited mobility. * having a positive straight leg raising test * receiving nonsteroidal anti-inflammatory drugs, hormonal therapy, or corticosteroid injections * individuals with tumors, fractures. ankylosing spondylitis.
comparison of 20-core versus 12-core prostate biopsy diagnostic performance in the detection of prostate cancer

Conditions: Prostate Cancer

Summary: the optimal number of prostate cores extracted during a prostate biopsy performed because of a suspected prostate cancer is still debated. the present consensus is to sample 12 cores. however, recent data published in the literature brought arguments in favour of a higher number, probably 20. this would have the advantages of decreasing the false negatives and the re-biopsy rate.


Eligibility criteria:
inclusion criteria: * patients older than 18 * patients with a psa value between 3 et 20 ng/ml * obtained informed consent * patients able to comply with the study protocol * patients covered by a social insurance exclusion criteria: * none
using allopurinol to relieve symptoms in patients with heart failure and high uric acid levels

Conditions: Heart Failure; Elevated Serum Uric Acid

Summary: the purpose of this study is to determine whether allopurinol is effective in relieving symptoms of patients with heart failure and high blood uric acid levels.


Eligibility criteria:
inclusion criteria: * nyha class ii-iv heart failure due to ischemic or non-ischemic cardiomyopathy. * left ventricular ejection fraction ≤ 40% by echocardiography- heart failure symptoms for 3 months despite standard treatment. * serum uric acid level ≥ 9.5 mg/dl. * at least one of the following additional markers of increased risk: hospitalization, er visit or urgent clinic visit for heart failure requiring iv diuretics within the previous 12 months; left ventricular ejection fraction ≤ 25; b-type natriuretic peptide level \> 250 pg/ml exclusion criteria: * hypertrophic or restrictive cardiomyopathy, constrictive pericarditis, biopsy-proven myocarditis, severe stenotic valvular disease, or complex congenital heart disease. * acute coronary syndrome, pci or cabg within 3 months. * current ventricular assist device or ventricular assist device or heart transplant likely within the next 6 months. * uncontrolled hypertension (i.e., sbp \> 170 mm hg or dbp \> 110 mm hg) * serum creatinine \> 3 mg/dl or estimated gfr \< 20 ml/min. * evidence of active hepatitis with alt and ast greater than 3x normal. * any condition other than hf which could limit the ability to perform a 6-minute walk test * any diseases other than hf which are likely to alter the patient's global perception of status or quality of life over a period of 6 months. * receiving treatment with allopurinol currently or within 30 days, or having symptomatic hyperuricemia which requires treatment with allopurinol.
a diagnostic test for familial mediterranean fever

Conditions: Familial Mediterranean Fever

Summary: familial mediterranean fever (fmf) is the most common auto-inflammatory disease (prevalence: 1-5 / 10,000 inhabitants). it is due to mutations of the mefv gene, encoding variants of the pyrin inflammasome. inflammasomes are protein complexes of innate immunity producing pro-inflammatory cytokines (interleukin-1β). in vitro, preliminary results demonstrated that activation of the pyrin inflammasome (measured by interleukin-1β concentration) by kinase inhibitors is significantly increased in fmf patients compared to subjects with a similar clinical picture, and healthy controls. in addition, a measure of cell death yielded significant results in differentiating patients from controls. the investigators hypothesize that this fast and simple functional test can serve as a diagnostic tool for fmf.


Eligibility criteria:
inclusion criteria: * clinical picture compatible with an familial mediterranean fever and an earlier genetic analysis finding a mutation of the mefv gene; * newly diagnosed or undergoing follow-up (without criteria of delay or evolutionary stage); * in the course of specific or non-specific treatment of the disease or without treatment; * for whom a blood test is planned as part of the routine care; * of whom the informed non-opposition has been collected (parental authorization in the case of a minor patient); exclusion criteria: * patient under legal protection or under safeguard of justice or any other measures of protection (guardianship, curatorship); * person unable to express his consent; * person in emergency situation, vital or not; * infection known to hiv and / or hbv and / or hcv
a study in adult and pediatric patients with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the purpose of this ascending dose group study is to assess the safety, tolerability, and effects of multiple dose levels of ins37217 and placebo followed by five days twice daily treatment with maximum tolerated dose administered by inhalation via the pari lc star nebulizer in adult and pediatric patients with cystic fibrosis


Eligibility criteria:
inclusion criteria: * fev1 40-70% (adults) * fev1 \>/=50% (pediatrics) * oxygen saturation \>90% * clinically stable * willing to stay overnight exclusion criteria: * abnormal renal or liver function * receiving corticosteroids exceeding 10mg/day or 20 mg every other day * received intravenous or aerosolized antibiotics 1 week prior to dosing
developmental hip dysplasia by ultrasonographic screening of asymptomatic infants at assiut university hospital

Conditions: Orthopedic Disorder

Summary: developmental dysplasia of the hip (ddh), formerly known as congenital dislocation of the hip, comprises a spectrum of abnormalities that include abnormal acetabular shape (dysplasia) and malposition of the femoral head.

the origin and pathogenesis of ddh are multifactorial. abnormal laxity of the ligaments and hip capsule is seen in patients with ddh. the maternal hormone relaxin may also be a factor. extreme hip flexion with knee extension, as in the breech position, tends to promote femoral head dislocation and leads to the shortening and contracture of the iliopsoas muscle. it was previously reported that ddh was the underlying aetiology in about 25 % of the performed hip replacements under the age of 40 years and the initial diagnosis age ranged from 0 to 39 years, with a mean of 8 years in these patients. the main purpose of a newborn hip screening program is to detect ddh as early as possible, so that early treatment can be given and the need for surgical treatment as well as the development of residual hip dysplasia can be avoided. ultrasonography offers distinct advantages compared with other imaging techniques: unlike plain radiography, it can distinguish the cartilaginous components of the acetabulum and the femoral head from other soft tissue structures, real-time us permits multiplanar examinations that can early determine the position of the femoral head in respect to the acetabulum; thus it provides the same type of information that can be obtained with arthrography, computerized tomography, or magnetic resonance imaging, but at lower cost, although ultrasonography is more expensive than plain radiography, it doesn't require sedation and doesn't involve ionizing radiation, unlike other techniques and it allows observation of changes in hip position with movement.

Eligibility criteria:
inclusion criteria: * all infants under the age of 6 months attending pediatric orthopedic outpatient clinics at assiut university hospital in the period between 1st of january 2017 to 30th of december 2017. exclusion criteria: * age older than 6 months * having any hip joint complaints
project aura: home trial of a home-based monitoring service

Conditions: Chronic Kidney Diseases

Summary: this is a data collection study to compare diagnostic methods of a prototype of a home monitoring device against laboratory testing in the hospital.

the device/monitoring system being developed measures the haemoglobin and haematocrit levels in blood from a single drop of blood. by measuring these blood parameters, participants are able to monitor their haemoglobin level at home. the use of the device will take place in the participant's home to simulate what the investigators believe will be the ideal location for people who would prefer to self-manage their condition. this study is a data collection study to evaluate the performance of the prototype.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years of age. * adequate english to participate in training sessions and use the analyser. * patients of the study site who are currently undergoing treatment for anaemia of ckd with esas. * patients who are not pregnant. * patients who do not have a bleeding disorder. * patients willing to perform self-tests 2-3 times a week. * patients capable of providing informed consent before attending training. * patients or patients with a carer capable of fine manipulation of the device and its consumables. * patients or patients with a carer who own a smartphone which can download the app related to this study. * patients or patients with carers who do not have eyesight limitations to be able to read the instructions on the screen of the prototype device. * patients who are not expected to have to start dialysis treatment during the course of this study. exclusion criteria: * does not have adequate english to participate in training or use the analyser without an interpreter. * patients of the study site who are not currently undergoing anaemia treatment with esas. * patients of the study site not willing to perform self-tests 2-3 times a week. * patients of the study site not capable of providing consent or have a suitable, legally acceptable representative present to provide consent before the trial. * patients who are pregnant. * patients with a bleeding disorder. * patients or their nominated carers who are not capable of fine manipulation of the device and its consumables. * neither patients or their nominated carers do not own a smartphone which can install the app related to this study. * patients or their nominated carers with eyesight limitations to not be able to read the instructions on the screen of the prototype device. * patients who are expected to start dialysis treatment during the study.
rad001 with paclitaxel and carboplatin in first line treatment of patients with advanced large cell lung cancer with neuroendocrine differentiation

Conditions: Carcinoma, Large Cell; Neuroendocrine Tumors

Summary: this is a multi-centric, open-label study evaluating the efficacy and safety of rad001 in patients with advanced (stage iv) lung cancer (large cell) with neuroendocrine differentiation treated with a combination of rad001 with paclitaxel and carboplatin.


Eligibility criteria:
inclusion criteria: 1. patients who give a written informed consent obtained according to local guidelines 2. histologically confirmed diagnosis of stage iv lung cancer of lc-nec type according to who classification: 1. histolocial analysis of newly diagnosed disease must not be older than 8 weeks from signed consent 2. relapse must be confirmed by histology 3. neuroendocrine differentiation 3. world health organisation (who) performance status grade ≤ 1 4. measurable disease 5. adequate bone marrow function 6. adequate liver function 7. adequate renal function exclusion criteria: 1. history or clinical evidence of central nervous system (cns) metastases. 2. presence of sclc cells 3. patients who have a history of another primary malignancy ≤ 3 years, with the exception of inactive basal or squamous cell carcinoma of the skin or cervical cancer in situ, early stages of breast cancer (lcis and dcis) and prostate cancer (stage t1a) 4. prior chemotherapy for the treatment of advanced lung cancer and/or not having recovered from the side effects of any other therapy (adjuvant treatment for earlier stages i-iii is allowed if finished at least one year before study entry) 5. patients who have received any investigational drug ≤ 28 days before starting study treatment or who have not recovered from side effects of such therapy 6. patients who have not recovered from the side effects of any major surgery or patients that may require major surgery during the course of the study 7. patients who have received prior therapy with rad001 or other mtor inhibitors 8. having any severe and/or uncontrolled medical conditions 9. women who are pregnant or breast feeding other protocol-defined inclusion/exclusion criteria may apply

Keywords: large cell carcinoma, lung cancer, neuroendocrine tumors, rad001
cbt for pediatric ocd: community training pilot

Conditions: Obsessive Compulsive Disorder

Summary: this study examines a training program for clinicians who work in mental health clinics that serve children with ocd. we will provide clinician training in conducting exposure-based treatments for children with ocd. the purpose of the project is to test the use of a new tool to enhance training in exposure-based treatments for clinicians. therapists will receive training and oversight from the researchers regarding the treatment procedures and use of the new tool. all children enrolled in the study will receive treatment by clinicians who are participating in this study. therapists and youth will be recruited separately for the study and will be assigned to work together.


Eligibility criteria:
inclusion criteria: * obsessive compulsive disorder is primary diagnosis exclusion criteria: * diagnosis of psychosis, pervasive developmental disorder, or mental retardation
hybrid duckett vs modified duckett urethroplasty for proximal hypospadias

Conditions: Proximal Hypospadias; Modified Duckett Urethroplasty

Summary: proximal hypospadias presents a serious anomaly for both infants and their care givers. a variety of techniques were described through decades. none of them is completely curable. hundred of modifications were adopted to the original techniques. during the current study, we will do hybrid duckett urethroplasty which is a staged procedure and compare it to modified duckett urethroplasty which is a single stage procedure.

two groups of infants diagnosed with proximal hypospadias will be allocated in two groups. group a will include cases of who will be operated upon using hybrid duckett urethroplasty. group b will include patients who will be operated upon using modified duckett urethroplasty. recruitment in either group will be done using sealed envelop method. in group a patient will have a double face duckett tube which will be transferred to the ventral of the penis. the tube will be secured in place however, no proximal anastomosis with the meatus. the anastomosis will be scheduled six months later. in group b patients a double face duckett tube will be transferred to the ventral aspect of the penis with completion of the anastomosis with the proximal meatus at the same session. the primary out come will be completion of the procedure and restoration of the urethral continuity. secondary out come will the cosmetic appearance

Eligibility criteria:
inclusion criteria: * all infants and children with proximal hypospadias exclusion criteria: * disorders of sex developments * previous penile surgery * circumcised children * crippled penis * refusal of the plan of the management by the care givers

Keywords: proximal hypospadias staged repair duckett urethroplasty urethrocutaneous fistula chodree
covert saccade triggers in bilateral vestibular hypofunction

Conditions: Reflex, Abnormal; Bilateral Vestibulopathy; Healthy Volunteers

Summary: patients with chronic bilateral vestibular hypofunction may suffer from a visual instability during head movement called oscillopsia. visual consequence of vestibular deficit can lead to a severe impairment of their quality of life. however, correcting saccades during rapid head movement, called covert-saccades, have been more recently identified. these saccades, which occur during the head movement in patients with vestibular hypofunction, present a very short latency. they could compensate for the lack of vestibular-ocular reflex and greatly decrease oscillopsia and visual impairment. the triggering of these covert-saccade is still not known. they could be of visual origin but the short latency is unusual. the objective of this study is to evaluate the potential role of visual trigger in 12 patients with chronic bilateral areflexia, using different visuo-vestibular conditions. the latency of simple visually guided saccades will also be tested in the group of patients and a group of 12 healthy controls.


Eligibility criteria:
inclusion criteria: * for all : * age from 18 to 90 * understanding of the experimental instructions * informed consent * for patients : bilateral vestibular hypofunction with regards to the criteria of the of the barany society a. chronic vestibular syndrome with at least three of the following symptoms 1. postural imbalance 2. unsteadiness of gait 3. movement-induced blurred vision or oscillopsia during walking or quick head/body movements 4. worsening of postural imbalance or unsteadiness of gait in darkness and/or on uneven ground b. no symptoms while sitting or lying down under static conditions c. bilaterally reduced or absent angular vor function documented by * bilaterally pathological horizontal angular vor gain \< 0.6, measured by the video-hit5or scleral-coil technique and/or * reduced caloric response (sum of bithermal max. peak spv on each side \< 6°/sec7)and/or * reduced horizontal angular vor gain \< 0.1 upon sinusoidal stimulation on a rotatorychair (0.1 hz, vmax = 50°/sec). d. not better accounted for by another disease \* for healthy control no ent or neurological disorders exclusion criteria: * corrected visual acuity lower than 5/10 * other conditions leading to oscillopsia or ataxia * oculomotor palsy, ocular instability in primary position * treatment that may affect ocular motility (psychotropes) * cervical rachis pathology with instability * cochlear implants * non-stabilized medical disease * pregnant women * patients under tutelage * patient without social security

Keywords: saccadic eye movements bilateral vestibulopathy bilateral vestibular hypofunction
insulin and insulin pulses during fasting

Conditions: PreDiabetes

Summary: fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. however, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. the proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.

decreased insulin action increases glucagon concentrations. in rodents, insulin signaling restrains glucagon secretion. it is unclear if this is the case in all (subtypes of) prediabetes. impaired hepatic insulin action exacerbates glucagon's effects on endogenous glucose production. also, insulin resistance in the β-cell impairs negative feedback inhibition of insulin secretion. this leads to hyperinsulinemia in rodents and humans. how these variables interact is unknown. this experiment will determine how insulin variably regulates fasting glucagon (and insulin) secretion directly, or indirectly, in prediabetes. the inability of the proinsulin to insulin ratio to reliably predict β-cell integrity, endoplasmic reticulum stress and β-cell function has led to the identification of novel markers of β-cell health. in addition, the relationship of glucagon and insulin pulses will be quantified. preliminary data shows that there is heterogeneity in these relationships even in normal fasting glucose. th experiment will also determine how islet hormone / glucose crosstalk and pulse characteristics contribute to prediabetes.

Eligibility criteria:
inclusion criteria: * people with normal or impaired fasting glucose and normal or impaired glucose tolerance exclusion criteria: 1. hba1c \> 6.5% 2. bmi ≥ 35 kg/m2 3. use of any glucose-lowering agents including metformin or sulfonylureas. 4. for female subjects: positive pregnancy test at the time of enrollment or study 5. history of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy. 6. active systemic illness or malignancy. 7. symptomatic macrovascular or microvascular disease. 8. hematocrit \< 35%

Keywords: insulin secretion glucagon secretion endogenous glucose production glucose disappearance